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1. Introduction 
Autism spectrum disorders (ASDs) encompass a group of chronic developmental disorders 
characterized by repetitive or stereotypic behaviors, interests and activities, along with marked 
impairments in a child’s ability to socialize and communicate. These debilitating conditions 
impact every aspect of the life of a child and his/her family. Modern advances in science and 
technology have provided successful explanations and interventions for many previously life-
threatening conditions such as bacterial meningitis and extreme prematurity. However, a 
scientific cause or definitive treatment for ASDs remains elusive. This lack of evidence 
regarding the biological causes of ASDs and successful, standardized treatment modalities 
challenges both parents/caregivers and health care providers in their understanding of these 
conditions, and effectively addressing the needs of this pediatric population. In some 
instances, the lack of evidence has fueled the development of hypotheses and possible 
associations based on the publication of case reports and small cohort studies. 
The prevalence of ASDs has increased over the past several decades, but it is unclear 
whether this is due to a true increase, increasing awareness, or differences in the methods 
used to diagnose these conditions and assess their prevalence. Given the irrefutable 
increase in the prevalence of ASDs, there has been interest in both genetic influences and 
environmental exposures that may have led to this increase over the past several decades. 
Although a small proportion of ASDs are associated with known congenital conditions, 
and several genes involved in ASDs have been identified, in most cases the etiology of 
ASDs is unknown. Some of the environmental triggers for ASDs that have been 
postulated include lack of breastfeeding, supplemental feeding with infant formulas that 
do not contain docosahexaenoic acid and arachidonic acid supplementation, childhood 
vaccinations, the use of acetaminophen and other analgesics, certain viral infections, and 
sundry other environmental exposures. Among these exposures, vaccinations have 
received the most widespread interest and attention by both the lay public as well as the 
medical and scientific communities. Young children are receiving more vaccines than 
ever, with multiple vaccines given at each visit, to provide protection against a plethora of 
infectious diseases. ASDs are often diagnosed in children at about the same chronologic 
age as the peak time for vaccine delivery. Unfortunately, a small, but vocal minority of 
people have attributed the rise in rates of ASDs to the increase in childhood vaccinations, 
despite the lack of rigorous scientific evidence to support this contention. The question 
about vaccines and ASDs continues to cause conflict between public health authorities 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
320 
and worried parent groups. This chapter will provide further details of the arguments on 
both sides and an analysis of the scientific evidence that supports the view that ASDs and 
vaccines are unlikely to be linked. 
2. Vaccines - victims of their own success? 
Vaccination is among the greatest achievements of modern medicine, leading to the 
eradication of naturally occurring smallpox and the near elimination of polio [1]. Most of the 
lay public as well as many scientists and physicians do not realize that the first vaccines 
against smallpox and rabies proved their effectiveness even before the identification of 
viruses as infectious agents [2]. Vaccination has a short history in medicine and public 
health when measured against the centuries during which human beings have fought 
desperately to prevent and treat various plagues and pestilences. Routine vaccination of 
large populations is a phenomenon of the 20th century [3]. Despite its relatively recent entry 
into the field of medicine and public health, vaccination has helped in the world-wide 
eradication/control of 12 major infectious diseases, including smallpox, diphtheria, tetanus, 
yellow fever, pertussis, Haemophilus influenzae type b disease, poliomyelitis, measles, 
mumps, rubella, typhoid and rabies [3]. In the United States, vaccination has contributed to 
the significant decline in morbidity from nine vaccine-preventable diseases and their 
complications between 1900 and 1999 (Table 1) [4]. Vaccines have been described as the 
single most life-saving accomplishment of the 20th century [5]. 
 
=========================================================== 
                                 Baseline 20th century          1998 Provisional         % 
Disease                        annual morbidity                  morbidity         Decrease 
----------------------------------------------------------------------------------------------------------- 
Smallpox                           48,164                     0               100% 
Diphtheria                        175,885                     1               100% 
Pertussis                            147,271                 6,279        95.7% 
Tetanus                               1,314                  34              97.4% 
Poliomyelitis (paralytic)  16,316                    0             100% 
Measles                              503,282         89               100% 
Mumps                              152,209                  606              99.6% 
Rubella                                47,745                  345            99.3% 
Congenital rubella              823                      5              99.4% 
 syndrome 
Haemophilus                       20,000                  54          99.7% 
 influenzae  type b 
------------------------------------------------------------------------------------------------------------ 
Table 1. Baseline 20th century annual morbidity and 1998 provisional morbidity from nine 
diseases with vaccines recommended before 1990 for universal use in children - United States  
Parents and many health care providers of the 21st century, particularly in more developed 
areas of the world such as the United States and Western Europe, have limited or no 
experience with the devastating effects of these diseases. In the United States public health 
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officials now recommend 28 to 31 vaccine doses before the age of 18 years, many of which 
are administered together to provide protection early in life, for the convenience of families 
and health care providers, and to decrease distress to the infant. Public health experts 
recommend that 95% of the population be vaccinated to provide herd immunity and 
minimize the possibility of resurgence of these deadly infections. However, parents in 
developed countries who have not seen these diseases or their disastrous consequences 
sometimes feel that they are being pressured into immunizing their children involuntarily 
for public good rather than personal benefit [6]. Some parents even perceive a greater risk to 
their children from vaccination than from the diseases themselves, not recognizing that the 
threat from these diseases is reduced simply because we do have effective vaccines to 
prevent them. Vaccination has thus regrettably become a polarized issue with some parents 
stressing their own child’s well-being at the one extreme and health experts advocating for 
public health outcomes on the other extreme. 
3. Genesis of the “vaccines cause autism” theory 
One of the first claims that vaccines might cause autism was made in a book entitled “A 
Shot in the Dark” by Harris L. Coulter and Barbara Loe Fisher [7]. In it the authors wrote, 
“With the increasing number of vaccinations American babies have been required to use has 
come increasing numbers of reports of chronic immune and neurologic disorders … 
including … autism.” At the time, little attention was paid to this assertion. The hypothesis 
received far greater support after a British physician and researcher Dr. Andrew Wakefield 
along with 12 co-authors published an article describing abnormal gastrointestinal features 
among 12 children who had been referred to their university pediatric gastroenterology 
clinic [8]. All of the children were reported to have some type of developmental disorder, 
and 9 of them had been diagnosed with autism. In 6 of these 9 children, either the parent or 
a physician had linked the onset of developmental regression with the receipt of the MMR 
vaccine. In this paper, Wakefield et al. proposed an elaborate sequence of events: that 
measles virus from the live-attenuated MMR vaccine caused intestinal inflammation, the 
inflamed intestines became “leaky”, allowing undefined harmful proteins to enter the 
bloodstream, travel to the brain and cause autism. In 2000, Wakefield and colleagues 
published a second paper in which white blood cells in the same 9 autistic children (with 
what was now referred to as “autistic enterocolitis”) were examined for the presence of 
measles virus [9]. Using polymerase chain reaction, the authors reported that measles virus 
RNA fragments were found in 3 out of the 9 children, but in none of 22 controls, lending 
credence to the “leaky-gut” theory [9].  
Additional theories of the putative association between vaccines and ASDs include:  
1. Concern about the mercury-containing preservative thimerosal (which was used in 
childhood vaccines for many years) and its potential toxic effects on the developing 
central nervous system in children; 
2. Worry that a combination of MMR and thimerosal-containing vaccines produces 
additive or synergistic toxic insults on children’s brains;  
3. Apprehension related to the simultaneous administration of multiple vaccines which 
might “overwhelm” or “weaken” the relatively immature immune system in young 
children.  
These theories will be explored later in this chapter, but let us first further discuss the 
most well-known controversy surrounding vaccines and ASDs. 
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4. Impact of the “MMR causes autism” scare 
As a consequence of the publications by Wakefield and his colleagues, many parents 
anxious about the risk of autism, particularly in the UK, began to refuse the MMR vaccine 
for their children. After the controversy began, the MMR vaccination compliance dropped in 
the UK from 92% in 1996 to 82% in 2002 [10]. In some parts of London, it was as low as 62% 
in 2003, far below the rate needed to avoid an epidemic of measles [10]. By 2006, coverage 
for MMR for children at 24 months of age in the UK was 85%, significantly lower than the 
94% coverage rate for other vaccines [11]. Predictably, the fall in vaccination rates for MMR 
vaccine was followed by an increase in the incidence in the UK of two of the three diseases 
that are prevented by it. In 1998 there were 56 confirmed cases of measles in the UK. By the 
first five months of 2006, there were 449 cases of measles reported in the UK, with the first 
death since 1992. As expected, the cases occurred in inadequately vaccinated or 
unvaccinated children [12].  
Mumps cases also began rising in 1999 after many years, and by 2005 the UK was in the 
midst of a mumps epidemic with almost 5000 reports in the first month of 2005 alone [13]. A 
total of 56,390 notified cases of mumps were reported in England and Wales that year [14]. 
Interestingly, most patients were aged between 15 and 24 years, too old to have received the 
routine MMR vaccine around the time the paper by Wakefield et al. was published, and too 
young to have contracted natural mumps as a child. With the decline in mumps that 
followed the introduction of the MMR vaccine in the UK, these individuals had not been 
exposed to the disease, and therefore had no immunity, either natural or vaccine-induced. 
Once immunization rates began to decline following the controversy and the disease re-
emerged, they were susceptible to infection [14].  
Measles and mumps cases continued in 2006, at incidence rates 13 and 37 times greater than 
their respective 1998 levels [15]. Two children were severely and permanently injured by 
measles encephalitis in London [16]. Measles outbreaks also resulted in casualties in nearby 
countries. Three deaths and 1,500 cases of measles were reported in an outbreak in Ireland, 
which occurred as a direct result of decreased vaccination rates following the MMR scare 
[16]. Another study reported the hospitalization of 111 cases of measles mostly with 
pneumonia, tracheitis or dehydration, with 13 of them requiring ICU admission and 7 of the 
children needing mechanical ventilation [17]. One editorial has described this as the 
“fallout” of the paper published by Wakefield et al. [18]. In 2008, for the first time in 14 
years, measles was declared to be endemic again in the UK. This was caused by the 
preceding decade's low MMR vaccination rates, which in turn created a population of 
susceptible children who could spread the disease [15]. MMR vaccination rates for English 
children remained at 85% in 2007–08, unchanged from the year before and at too low a level 
to prevent serious measles outbreaks [19]. In May 2008, a British 17-year-old with an 
underlying immunodeficiency died of measles [15]. In 2008, measles epidemics were 
reported from Austria, Italy, and Switzerland [15].  
In a study conducted in the US, selective MMR nonreceipt, occurring in as few as 0.77% of 
children in the 1995 cohort, rose to 2.1% according to the 2000 National Immunization 
Survey [20]. Children included in the 2000 National Immunization Survey were born at 
around the time that the putative link between MMR and autism surfaced in the medical 
literature. Sporadic importations of measles into the US had occurred since the disease was 
declared eliminated from the US in 2000. However, in 2008, a measles outbreak occurred in 
the US involving 16 states [21]. Of the individuals affected, 94% were US residents, 93% 
were unvaccinated and 86% of the cases were imported (69% from Europe).  
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5. Lack of evidence to support the “MMR causes autism” theory 
The scientific limitations of the paper published by Wakefield et al. [8] were pointed out 
soon after it first appeared [22]. It was noted that the paper reported on a small series of 
cases with no controls, linked three common clinical conditions, and relied on the recall and 
beliefs of parents [23]. Several large population- and ecologic-based studies were conducted 
over the following decade that consistently found no evidence of a link between the MMR 
vaccine and autism and failed to provide any support for Wakefield’s theory [24-27]. In fact, 
the lack of an association between MMR vaccination and autism in children is supported by 
19 additional scientific studies performed by diverse groups of investigators using various 
research methodologies involving disparate groups of patients over more than a decade [28-
46]. Several of these studies have been discussed in detail in 4 review articles [47-50]. In 
other words, despite significant efforts by numerous groups of investigators, the findings of 
Wakefield et al. [8] could not be replicated or confirmed. Interestingly, in a case-control 
study conducted in Poland, where the MMR vaccine was introduced later than in most other 
European countries, the investigators report that the risk of autism was lower in children 
who received the MMR vaccine than in those who did not [44]. The authors do not claim a 
“protective” effect of the vaccine, but correctly recognize that the decreased risk of autism 
among vaccinated children may have been due to other confounding factors in their health 
status such as, healthcare workers or parents who may have noticed signs of developmental 
delay or disease before the actual autism diagnosis and for this reason have avoided 
vaccination [44]. This type of critical and honest analysis is missing from studies that 
support the contention that the MMR vaccine is associated with ASDs [51-53]. 
In 2004, 10 of the 12 coauthors of Wakefield’s acknowledged that “no causal link was 
established between MMR vaccine and autism as the data were insufficient” in their original 
paper and asked to “formally retract the interpretation” of their findings [54]. Moreover, an 
investigation by D’Souza et al. using a larger sample size than Wakefield and his colleagues’ 
original study [9], failed to reveal persistence of measles virus RNA in the peripheral blood 
of children with ASDs [55]. Two additional studies reported no detectable measles virus 
genome sequence in the blood of autistic children who had received MMR vaccination [56, 
57]. Further, in a case-control study conducted by Hornig et al., ileal and cecal tissues from 
25 children in the US with autism and gastrointestinal (GI) disturbances and 13 children 
with GI disturbances alone (controls) undergoing clinically-indicated ileocolonoscopy, were 
evaluated by real-time reverse transcription (RT)-PCR for presence of measles virus RNA in 
three laboratories blinded to diagnosis, including one wherein the original findings 
suggesting a link between measles virus and ASDs were reported [58]. The authors reported 
no differences between case and control groups in the presence of measles viral RNA in the 
ileum and cecum [58]. 
Despite the scientific difficulty with proving a negative, the Institute of Medicine (IOM) in a 
report on vaccine safety has stated conclusively that there is no causal relationship between 
the administration of the MMR vaccine and the onset of ASDs [59]. This eighth and final 
report of the Immunization Safety Review Committee examined the hypothesis that 
vaccines, specifically the MMR vaccine and thimerosal-containing vaccines, are causally 
associated with autism. The committee reviewed the extant published and unpublished 
epidemiological studies regarding causality and studies of potential biologic mechanisms by 
which immunizations might cause autism and concluded that the body of epidemiological 
evidence favored rejection of a causal relationship between the MMR vaccine and autism 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
324 
[59]. The committee further found that potential biological mechanisms for vaccine-induced 
autism that have been generated to date are theoretical only [59]. Thus, the MMR vaccine 
continues to be safe, efficacious and recommended by the public health authorities and 
supported by the vast majority of medical professionals. Nevertheless, despite the large 
body of scientific evidence to the contrary, Barbara Loe Fisher continues to support her 
initial theory that vaccines cause autism [60]. 
6. MMR and autism - honest error or deliberate fraud? 
The Office of Research Integrity in the United States defines fraud as fabrication, 
falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting 
research results [61]. They further explain that: 
a. Fabrication is making up data or results and recording or reporting them. 
b. Falsification is manipulating research materials, equipment, or processes, or changing 
or omitting data or results such that the research is not accurately represented in the 
research record. 
c. Plagiarism is the appropriation of another person's ideas, processes, results, or words 
without giving appropriate credit. 
d. Research misconduct does not include honest error or differences of opinion. 
Editors at the BMJ claim that it has taken the diligent skepticism of one man, Brian Deer, a 
journalist standing outside the realms of medicine and science, to show that the initial paper 
by Wakefield et al. [8] was in fact an elaborate fraud [62]. In a series of articles published this 
year, Deer reports on how Wakefield altered numerous facts about his patients’ medical 
histories in order to support his claim to have identified a new syndrome [63]; how his 
institution, the Royal Free Hospital and Medical School in London, supported him as he 
sought to exploit the ensuing MMR scare for financial gain [64]; and how key players failed 
to investigate thoroughly in the public interest when Deer first raised his concerns [65]. Deer 
published his first investigation into Wakefield’s paper in 2004 [66]. This uncovered the 
possibility of research fraud, unethical treatment of children, and Wakefield’s conflict of 
interest through his involvement with a lawsuit against manufacturers of the MMR vaccine 
[62]. Building on these findings, the General Medical Council (GMC) of the UK launched 
proceedings that focused on whether the research conducted by Wakefield et al. [8] was 
ethical.  
While the disciplinary panel was examining the children’s medical records in public, Deer 
compared them with what was published in the Lancet article. His focus was not on whether 
the research was ethical, but whether it was factual. Through interviews, documents, and 
data made public at the GMC hearings as well as his investigations spanning several years, 
Deer has unearthed clear evidence of falsification in Wakefield et al.’s [8] paper. He found 
that in every one of the 12 cases reported by Wakefield et al. [8], there was misrepresentation 
or undisclosed alteration, and that in no single case could the children’s medical records be 
fully reconciled with the descriptions, diagnoses, or histories published in the article. The 
editors of the BMJ have questioned the origins of the falsified data and lay the blame 
squarely upon Andrew Wakefield [62]. They question whether it is possible that he was 
wrong, but not dishonest: that he was so incompetent that he was unable to fairly describe 
the project, or to report even one of the 12 children’s cases accurately, and conclude that the 
article resulted not from honest errors, but a deliberate attempt to defraud [62]. They base 
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their conclusion on the contention that a great deal of thought and effort must have gone 
into drafting the paper to achieve the results he wanted, since the discrepancies all led in 
one direction and the misreporting was gross [62]. 
7. Consequences of the “MMR causes autism” fraud 
Nearly 12 years after its original publication, the journal Lancet fully retracted the article by 
Wakefield et al., based on several elements of the paper being proven to be false [67]. The 
GMC completed its longest-ever “fitness to practice” hearing, and based upon it withdrew 
Dr. Wakefield’s license to practice medicine [68]. Andrew Wakefield was branded as being 
“dishonest,” “unethical,” and “callous” [69]. His associate Professor John Walker-Smith, the 
senior clinician in the project, was found to have presided over “high risk” research without 
clinical indication or ethical approval, and also struck off the medical register [70]. Further 
details about this controversy and autism research have been published in a couple of recent 
books [71, 72].  
The Wakefield case and its aftermath have resulted in a reevaluation of how biomedical 
research is regulated. There have been calls for a national Health Research Agency to be 
established in the UK to oversee the regulation and governance of health research [73]. 
Others have advocated for public access to raw data, arguing that the apparent 
discrepancies between the patient records and the data in the article by Wakefield et al. [8] 
might have come to light sooner, perhaps even before publication, had the raw data been 
available for public scrutiny [74]. Opel et al. propose that as part of an effort to improve 
research integrity traditional hierarchies and authority gradients need to be bypassed in 
order to empower everyone in the research enterprise-especially those on the front lines, 
such as research assistants, data analysts, and project managers-to raise questions and be 
able to report suspected misconduct without fear of reprisal [75]. They suggest that the 
ability to investigate research incidents needs to be strengthened using the best tools and 
techniques available to protect the safety of research subjects [75]. They also assert that the 
customs and culture around biomedical research need rethinking and reform. They point to 
the disastrous impact that Wakefield’s flawed study has had on vaccine coverage, 
recrudescence of vaccine-preventable diseases and erosion of the public’s trust in science, 
and exhort rapid action to remedy the current system of ensuring research integrity [75]. 
Based on the above referenced body of knowledge, few people could deny that Wakefield et 
al.’s paper was fatally flawed both scientifically and ethically, if not outright fraudulent. 
Unfortunately, an allegation is remembered long after it has been disproved. In a postal 
survey of parent's decisions, attitudes and use of information about MMR immunization in 
the UK, Casiday et al. report that both MMR-accepting and refusing parents were 
supportive of immunization, but had a high level of concern about the safety of vaccines 
[76]. A web-based survey of parents conducted in 2009 in the US, showed that while most 
parents agreed that vaccines protect their child(ren) from diseases, more than half of the 
respondents also expressed concerns regarding serious adverse effects of vaccines [77]. 
Overall, 11.5% of the parents had refused at least 1 vaccine that their doctor had 
recommended for their child(ren), with 17.7% refusing the MMR vaccine [77]. A quarter of 
the survey responders either strongly agreed or agreed with the statement “Some vaccines 
cause autism in healthy children” [77]. Wakefield’s legacy promises to live on. 
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8. Origins of the thimerosal and autism controversy  
Another hot button issue that has been debated in relationship to the onset of ASDs is 
exposure to thimerosal, a preservative that has been present in vaccines since the 1930s [78]. 
Multidose vaccine vials have the antibacterial agent thimerosal added to preserve the 
sterility of the contents. Thimerosal contains 49.6% mercury by weight and metabolizes into 
ethylmercury and thiosalicylate. Towards the end of the 20th century, the US government 
became aware of and concerned about mercury exposure in the general population [79] and 
the US Environmental Protection Agency (EPA) published standards of safe limits of oral 
methylmercury exposure particularly from fish and shellfish [80, 81]. Statements from the 
EPA clearly indicate that people in the U.S. are mainly exposed to organic methylmercury, 
when they eat fish and shellfish that contain it. The EPA identifies factors that determine 
how severe the health effects are from mercury exposure including: 
 the chemical form of mercury  
 the dose  
 the age of the person exposed (the fetus is the most susceptible)  
 the duration of exposure  
 the route of exposure -- inhalation, ingestion, dermal contact, etc.  
 the health of the person exposed. 
Various agencies have developed guidelines for “safe” exposure to methylmercury, including 
the EPA [82, 83], U.S. Agency for Toxic Substances and Disease Registry (ATSDR) [84], the 
U.S. Food and Drug Administration (FDA) [85], and the World Health Organization (WHO) 
[86]. These exposure levels ranged from 0.1 µg/kg body weight/day (EPA) to 0.47 µg/kg 
body weight/day (WHO), and while clearly different, were within the same order of 
magnitude. The various mercury guidelines were based on epidemiological and laboratory 
studies of methylmercury, whereas thimerosal as noted above is a derivative of ethylmercury. 
Because they are different chemical entities i.e. ethyl versus methylmercury, different 
toxicological profiles are expected for the two compounds. It should be recognized that 
there was uncertainty in applying the methylmercury-based guidelines to thimerosal. The 
FDA has noted that these guidelines may be used as screening tools in risk assessment to 
evaluate the "safety" of mercury exposures, but are not meant to be bright lines above which 
toxicity will occur [87].  
In 1997, Frank Pallone, a U.S. congressman from New Jersey, added an amendment to a 
(FDA) reauthorization bill which gave the FDA 2 years to “compile a list of drugs and foods 
that contain intentionally introduced mercury compounds and provide a quantitative and 
qualitative analysis of the mercury compounds in the list” [88]. The bill was signed into law 
as the FDA Modernization Act of 1997, and garnered little public or press attention at the 
time. To abide by this law, the FDA conducted a comprehensive review of the use of 
thimerosal in childhood vaccines in 1999, and notably, found no evidence of harm from the 
use of thimerosal as a vaccine preservative, other than local hypersensitivity reactions [89]. 
The maximum cumulative exposure to mercury from vaccines in the recommended 
childhood immunization schedule at the time, was found to be within acceptable limits for 
the methylmercury exposure guidelines set by FDA, ATSDR, and WHO. However, 
depending on the vaccine formulations used and the weight of the infant, some infants 
could have been exposed to cumulative levels of mercury during the first six months of life 
that exceeded EPA recommended guidelines for safe intake of methylmercury. 
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As more thimerosal-containing vaccines were added to the recommended infant and child 
immunization schedule, theoretical concerns based on the cumulative amounts of 
thimerosal that a child was receiving in the first two years of life were raised. As a 
precautionary measure, the US Public Health Service (USPHS) (which includes the FDA, 
National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and 
the Health Resources and Services Administration (HRSA)) and the American Academy of 
Pediatrics issued two Joint Statements, urging vaccine manufacturers to reduce or eliminate 
thimerosal in vaccines as soon as possible [90, 91]. This was done through an “abundance of 
caution,” even though there was no evidence that thimerosal-containing vaccines 
contributed to toxic mercury levels in children, and in fact ethylmercury does not have the 
neurotoxic effects of methylmercury. The action taken by the USPHS and AAP had 
significant, unintended ripple effects on the general public’s concerns about vaccine safety 
in young children. Beginning in 2000, many parents founded advocacy groups based on the 
belief that thimerosal had caused their children’s autism [92]. The birth dose of hepatitis B 
vaccine which in 1999 contained thimerosal was subsequently withheld from many children 
and the hepatitis B vaccination campaign in the US experienced a serious setback [93]. 
Although thimerosal-free hepatitis B vaccines became available shortly thereafter, the effort 
to vaccinate infants at birth remains a challenge in some areas.  
9. Insufficient scientific evidence linking thimerosal with autism  
The signs and symptoms of autism are clearly distinct from those of mercury poisoning. 
Children with mercury poisoning show characteristic motor, speech, sensory, psychiatric, 
visual, and head circumference changes that are fundamentally different from those of or 
absent in children with autism. Concerns about mercury as a cause of autism therefore 
seemed biologically implausible [94]. Nevertheless, it began to be suggested that there may 
be adverse neurological effects including autism due to ethylmercury exposure from the use 
of thimerosal in vaccines [95-103]. Notably, most of the studies that reported an association 
of thimerosal with neurodevelopmental disorders including autism were performed by the 
same group of researchers [98-103], using the Vaccine Adverse Events Reporting System 
(VAERS) as their data source. The VAERS is a passive reporting system to which anyone can 
report adverse events that are purported to be associated with vaccines. Goodman and 
Nordin have shown that most reports to the VAERS system in recent years regarding 
thimerosal were influenced by litigation, and are therefore unsuitable for scientific study 
[104]. In other words, most of the adverse reports regarding thimerosal and autism were 
related to pending lawsuits for vaccine injury. This severely biased the dataset, and it should 
not have been used to assign causality. 
Meanwhile, several other studies performed by various groups of researchers did not 
support the postulated association between thimerosal and ASDs [33, 105-112]. Three 
ecological studies were performed in 3 different countries comparing the incidence of 
autism with thimerosal exposure from vaccines [33, 109, 110]. In each case, thimerosal had 
been removed from childhood vaccines, allowing robust comparisons of vaccination with 
thimerosal-containing and thimerosal-free products. A large study from Denmark showed 
no difference in the incidence of autism among children who had received vaccines 
containing different amounts of thimerosal [109]. Despite the removal of thimerosal from 
vaccines in 1992 in Sweden and Denmark, the incidence of autism increased steadily from 
1990 to 2000 [110]. Thimerosal exposure and pervasive developmental disorder diagnosis 
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were found to be independent variables in a study from Canada [33]. In this study, the 
highest rates of pervasive developmental disorder were found in children who had received 
thimerosal-free vaccines [33]. 
Additional epidemiologic studies also failed to show any association between thimerosol 
exposure and ASDs. In a large study from Denmark, researchers found that the risk of 
autism did not differ between children vaccinated with thimerosal-containing vaccines and 
those vaccinated with thimerosal-free vaccines or between children who received larger or 
smaller quantities of thimerosal [107]. They also reported that the rates of autism increased 
after the removal of thimerosal from all vaccines. In the United States, researchers at the 
CDC used the Vaccine Safety Data Link to examine the health records of 140,887 children 
born during 1991–1999, including over 200 children diagnosed with autism [111]. They 
found no relationship between receipt of thimerosal-containing vaccines and autism. In a 
large study conducted in the UK, researchers evaluated the vaccination records of 100,572 
children born during 1988–1997, 104 of whom were affected with autism [105]. No 
relationship between thimerosal exposure and developmental disorders was observed. In a 
separate study from the UK, researchers prospectively followed 12,810 children born during 
1991–1992, for whom they had complete vaccination records, and again found no 
relationship between early thimerosal exposure and subsequent adverse neurological or 
psychological outcomes [106].  
A long-term follow-up study by the CDC showed that early thimerosal exposure from 
vaccines did not cause adverse neuropsychological outcomes after 7-10 years [113]. In 
another long-term follow-up study performed in Italy, 2 groups of children with exposure to 
different doses of thimerosol were examined [114]. Among the 24 neuropsychological 
outcomes that were evaluated, only 2 were significantly associated with thimerosal 
exposure. The authors noted that due to the large number of statistical comparisons 
performed, the few associations found between thimerosal exposure and 
neuropsychological development might be attributable to chance [114]. The associations 
found, although statistically significant, were based on small differences in mean test scores, 
and their clinical relevance could not be determined. A case-control study was conducted in 
3 managed care organizations (MCOs) in the US that included 256 children with ASD and 
752 matched controls [115]. The authors report that in their study, prenatal and early-life 
exposure to ethylmercury from thimerosal-containing vaccines and immunoglobulin 
preparations was not related to increased risk of ASDs [115]. Several scientific and public 
policy review committees have carefully evaluated the existing data and concluded that 
there was not sufficient evidence of a link between autism and thimerosal in vaccines [59, 
87, 116]. In fact, the Institute of Medicine’s 2004 evaluation included a strong statement that 
rejected the idea that thimerosal-containing vaccines cause autism, concluding that 
“…epidemiological evidence favors rejection of a causal relationship between thimerosal-
containing vaccines and autism” [116]. 
Interestingly, comparisons of methylmercury and ethylmercury tissue distribution following 
exposure in young mice [117] and monkeys [118] both reported significantly less mercury 
deposited in the brain following ethylmercury or thimerosal exposure, as compared to 
methylmercury exposure. The authors of these studies concluded that the clearance and tissue 
distribution of the two compounds differ significantly in animal models [117, 118]. The 
route of exposure (injection versus ingestion) to methylmercury also resulted in differences in 
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the amount of mercury deposited in the brain in mice, with exposure via intramuscular 
injection resulting in less mercury deposition than via ingestion [117]. In a study by 
Pichichero ME, et al., mercury levels in blood and other samples from infants who had 
received routine immunizations with thimerosal-containing vaccines were measured [119]. 
Blood levels of mercury did not exceed safety guidelines for methylmercury for all infants in 
this study. Further, mercury was cleared from the blood in infants exposed to thimerosal 
faster than would be predicted for methylmercury. Infants excreted significant amounts of 
mercury in stool after thimerosal exposure, thus removing mercury from their bodies. These 
results suggest that there are differences in the way that thimerosal and methylmercury are 
distributed, metabolized, and excreted. Thimerosal appears to be removed from the blood 
and body more rapidly than methylmercury in young children. Due to the differences in the 
biological behavior of these two compounds, the flaws in extrapolating the risk assessment 
of thimerosal by direct comparison with methylmercury are well described in a review by 
Aschner and Ceccatelli [120]. Another review article summarizes the studies investigating 
thimerosal exposure and the development of ASDs (Table 2) [121]. 
 
 Type of Study Outcome Measure 
Association with 
Thimerosal Exposure 
Andrews et al., 2004  Cohort  Autism  No 
Croen et al., 2008  Case-Control  Autism  No 
Geier and Geier, 2007 Case-Control  Autism  Yes 
Heron et al., 2004  Cohort  Developmental Disorders  No 
Hviid et al., 2003  Cohort Autism  No 
Madsen et al., 2003  Ecologic  Autism  No 
Miles and Takahashi, 2007 Cross-Sectional Autism  No 
Thompson et al., 2007  Cohort Neuropschological Functioning No 
Verstraeten et al., 2003  Cohort  Autism  No 
Young, Geier, and Geier, 2008 Ecologic  Autism  Yes 
Table 2. Studies Investigating Thimerosal Exposure with Autism and Other Developmental 
Outcomes. 
Thimerosal has been removed from all childhood vaccines in the US, but this has also 
increased production costs which are ultimately passed on to the consumer. Only some 
preparations of influenza vaccine still contain thimerosal (See Table 3). However, largely 
unfounded concerns about the adverse effects of thimerosal have made many parents 
reluctant to have their children receive this vaccine. What goes unrecognized by the lay 
public and even many health care providers is that influenza virus causes hundreds of 
thousands of hospitalizations and an average of 100 deaths among children every year. 
Mistakenly attempting to protect their children from a theoretical risk, these parents 
inadvertently place them at the real risk of being hospitalized or killed by influenza. An 
alarming recent trend has been that physicians, scientists, government policy advisors, and 
child advocates who publicly state that vaccines do not cause neurologic problems or autism 
have been harassed, threatened, and vilified, receiving hate mail and occasionally even 
death threats [92]. 
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Vaccine Brand Name Manufacturer Thimerosal Concentration1 
Mercury 
mcg/0.5 ml  
Anthrax BioThrax BioPort Corp 0 0 
DTaP  Tripedia sanofi pasteur * * 
Infanrix GlaxoSmithKline 0 0 
DAPTACEL sanofi pasteur 0 0 
DTaP-HepB-IPV  Pediarix GlaxoSmithKline 0 0 
DTaP-IPV-Hib  Pentacel sanofi pasteur 0 0 
DTaP-Hib  TriHIBit sanofi pasteur * * 
DTwP  All Products .01% 25 
DT  Diphtheria & Tetanus Toxoids Adsorbed 
USP multi-dose single dose  sanofi pasteur 
.01% 25 
* * 
Td  DECAVAC sanofi pasteur * * 
Tetanus and Diphtheria Toxoids 
Adsorbed  
sanofi pasteur * * 
Tdap  ADACEL sanofi pasteur 0 0 
Boostrix GlaxoSmithKline 0 0 
Tetanus Toxoid  Tetanus Toxoid Adsorbed USP 
sanofi pasteur 
.01% 25 
Tetanus Toxoid Adsorbed Adult Use .01% 25 
Booster .01% 25 
Hib  ActHIB sanofi pasteur 0 0 
Hiberix GlaxoSmithKline 0 0 
HibTITER Wyeth-Ayerst 0 0 
PedvaxHIB liquid (2) Merck 0 0 
Hib/HepB  Comvax (3) Merck 0 0 
Hepatitis A  Havrix GlaxoSmithKline 0 0 
Vaqta adult/pediatric  Merck 0 0 
Hepatitis B  Engerix-B preservative free GlaxoSmithKline 0 0 
Recombivax HB preservative free Merck 0 0 
Hep A-B Twinrix GlaxoSmithKline 0 0 
HPV Cervarix GlaxoSmithKline 0 0 
Gardasil Merck 0 0 
Influenza 2009/10 
Formula  
Afluria multi-dose single dose 
CSL Limited 
.01% 24.5 
0 0 
Agriflu Novartis 0 0 
Fluarix GlaxoSmithKline ≤1 
FluLaval GlaxoSmithKline .01% 25 
FluMist MedImmune 0 0 
Fluvirin Novartis .01% 24.5 
Fluzone 5 mL vial No Preservative  
sanofi pasteur 
.01% 25 
0 0 
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Vaccine Brand Name Manufacturer Thimerosal Concentration1 
Mercury 
mcg/0.5 ml  
Influenza A H1N1 
2009  
Influenza A (H1N1) 2009 Monovalent 
Vaccine multi-dose single dose  CSL Limited 
.01% 24.5 
0 0 
Influenza A (H1N1) 2009 Monovalent 
Vaccine multi-dose single dose  Novartis 
.01% 24.5 
 ≤1 
Influenza A (H1N1) 2009 Monovalent 
Vaccine multi-dose single dose  sanofi pasteur 
.01% 25 
0 0 
Influenza A (H1N1) 2009 Monovalent 
Vaccine  
GlaxoSmith Kline .01% 25 
Influenza A (H1N1) 2009 Monovalent 
Vaccine Live, Intranasal  
MedImmune 0 0 
IPV Japanese 
Encephalitis  
IPOL Ixiaro  commercial | military  sanofi pasteur  
Intercell Bio 
0 0 
JE-Vax sanofi pasteur 0.007%  
Meningococcal  Menactra sanofi pasteur 0 0 
MENOMUNE-A/C/Y/W-135 multi-dose 
single dose  sanofi pasteur 
.01% 25 
0 0 
Menveo Novartis 0 0 
MMR  M-M-R II   Merck 0 0 
MMR-Varicella ProQuad  Merck 0 0 
Polio IPOL  sanofi pasteur 0 0 
Pneumococcal  Prevnar  Wyeth-Ayerst 0 0 
Pneumovax 23  Merck 0 0 
Rabies RabAvert  Chiron 0 0 
IMOVAX  sanofi pasteur 0 0 
Rotavirus RotaTeq  Merck 0 0 
Typhoid Fever  Typhim Vi  sanofi pasteur 0 0 
Vivotif  Berna Biotch 0 0 
Varicella Zoster  Varivax   Merck 0 0 
Zostavax  Merck 0 0 
Yellow Fever  YF-VAX  sanofi pasteur 0 0 
1. A concentration of 1:10,000 is equivalent to a 0.01% concentration. Thimerosal is approximately 50% Hg by 
weight. A 1:10,000 concentration contains 25 mcg of Hg per 0.5 mL. (2). A previously marketed lyophilized 
preparation contained 0.005% thimerosal. (3). COMVAX is not approved for use under 6 weeks of age because of 
decreased response to the Hib component * This product should be considered equivalent to thimerosal-free 
products. This vaccine may contain trace amounts (<0.3 mcg) of mercury left after post-production 
thimerosal removal; these amounts have no biological effect. JAMA 1999;282(18) and JAMA 
2000;283(16).  
Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health. Available at 
www.vaccinesafety.edu. Accessed 4/17/11. 
Table 3. Thimerosal Concentration in Licensed Vaccines. 
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10. If vaccines are not to blame, why are ASDs increasing? 
The increase in prevalence of the ASDs may be explained by three reasons as described by 
Scahill et al. [122]. First, in 1994, with the release of the Diagnostic and Statistical Manual of 
Mental Disorders , 4th edition (DSM–IV), there was a broadening of the diagnostic criteria for 
autism. The DSM–IV also added criteria for Asperger’s syndrome and clarified the criteria 
for Pervasive Developmental Disorders-Not Otherwise Specified (PDD-NOS). Finally, better 
assessment methods have provided clarification across PDD diagnoses and improved the 
demarcation between PDD and non-PDD cases. Thus, more recent studies have overcome 
the systematic undercount of PDD cases in previous studies. The perceived increase in ASDs 
is therefore likely driven by broadened diagnostic criteria and increased awareness. 
11. Role of multiple vaccines and emergence of alternative schedules 
With the revelations of the likely fraudulent claims about the MMR vaccine causing ASDs 
and well-designed studies of thimerosal-containing vaccines failing to show an association 
with autism, alternative theories about the role of vaccines in causing ASDs have been 
proposed. The most prominent among these is that the simultaneous administration of 
multiple vaccines “overwhelms” or “weakens” the immature immune system in young 
children and through some interaction with the nervous system “triggers” autism in a 
susceptible host. Sensationalized cases in the media have given credence to this theory. The 
case that has garnered the most attention is that of a 9-year-old girl with a mitochondrial 
enzyme deficiency whose encephalopathy, which included features of ASD, was judged to 
have worsened following the receipt of multiple vaccines at age 19 months [123]. Her family 
was able to successfully obtain compensation through the US Vaccine Injury Compensation 
Program (VICP) which was developed in the 1980s to fairly compensate individuals who 
feel they have been harmed by a vaccine. In the wake of this case, despite reassurances by 
the CDC that the VICP’s action should not be interpreted as scientific evidence that vaccines 
cause autism, the theory that multiple vaccines given simultaneously can trigger autism has 
gained credence among the lay press and public. 
The idea that multiple vaccines given to young children might either overwhelm an 
immature immune system or generate a pathologic, autism-inducing autoimmune response 
is flawed for several reasons. Although the infant immune system is relatively naive, it is 
capable of generating a vast array of protective responses, starting at birth. In fact, vaccines 
represent a small fraction of the challenges to a young child’s immune system. For example, 
the average child is infected with 4-6 viruses per year [124], exposing its immune system to 
numbers of antigens that far exceed those present in simultaneously administered childhood 
vaccines. Proponents of the theory point to the increasing number of vaccines that are 
administered to young children. However, most people do not recognize that although the 
number of recommended childhood vaccines has increased during the past 30 years, with 
advanced technologies that are used to manufacture modern vaccines, the immunologic 
load has actually decreased. The childhood vaccines given today contain <200 bacterial and 
viral antigens, compared with >3000 of these immunological components in the vaccines 
administered to children in 1980 [125]. In fact, combinations of vaccines are actually known 
to induce immune responses that are comparable to those given individually [126].  
Susceptibility to non-vaccine-preventable infections does not differ in vaccinated and 
unvaccinated children [127–129]. Put in another way, vaccination does not appear to 
www.intechopen.com
 
Vaccines and Autism – An Unlikely Connection 
 
333 
suppress the immune system in young children in a clinically relevant manner. On the 
contrary, infections with some vaccine-preventable diseases are known to predispose 
children to severe, invasive infections with other pathogens [130,131]. Therefore, the 
available data suggest that vaccines do not “weaken” the immune system. Furthermore, it 
should be recognized that autism is not an immune-mediated disease such as multiple 
sclerosis. There is no evidence of immune activation or inflammatory lesions in the brains of 
autistic people [116]. Instead, new research suggests that genetic variation in neuronal 
circuitry that affects synaptic development in the brain might in part account for the 
symptoms of autism [132]. Therefore, the theory that an exaggerated or inappropriate 
immune response to vaccination results in autism is at variance with current scientific data 
that address the pathogenesis of autism. 
In 2007, Dr. Robert Sears, a pediatrician from Southern California published The Vaccine 
Book: Making the Right Decision for Your Child [133]. In it he offers 2 alternative schedules (that 
are not approved or endorsed by any public health authority or professional physician 
group) to parents who are concerned about vaccines so that they may delay, withhold, 
separate, or space out vaccines for their children. Dr. Sears has publicly stated that he isn't 
against vaccinations [134]. Instead, his book suggests an untraditional “alternative” 
schedule that delays vaccines or spaces them further apart. If parents are unwilling to 
vaccinate at all, he offers a separate “selective” schedule to encourage them to give their 
child(ren) at least the "bare minimum" of vaccinations. Healthcare providers are facing 
many parents who are questioning the need for immunization and insisting that their 
children receive vaccines according to Dr. Sears’ schedule, rather than that recommended by 
the CDC, the American Academy of Pediatrics, and the American Academy of Family 
Physicians. Most parents are unaware that no research studies have compared the incidence 
of autism in vaccinated, unvaccinated, or alternatively vaccinated children (i.e., schedules 
that spread out vaccines, avoid combination vaccines, or include only select vaccines) [135]. 
The problem with Dr. Sears’ schedules is the fact that it can take up to 5-6 years for children 
to complete their immunizations, during which some children will be at risk for contracting 
vaccine-preventable diseases due to lack of adequate immunity. Dr. Sears’ book has been 
described as dangerous by some, because it validates the pervasive myths that are currently 
scaring parents into making ill-informed decisions for their children [136]. 
12. Legal repercussions 
Perhaps inevitably in a litiginous society, the question of whether childhood vaccines cause 
autism has moved from the scientific into the legal realm [137-139]. Parents of children with 
autism have submitted thousands of claims to the federal VICP, seeking damages because 
they believe that their child’s autism was caused by vaccines. In 2002, to resolve such claims 
more expeditiously, the VICP announced that some “test cases” would examine the general 
causation question, putting aside the question of harm to any particular child. On February 
12, 2009, the U.S. Court of Federal Claims published decisions about these claims, which 
were considered as a group under the Omnibus Autism Proceeding. The Court, after 
reviewing 5,000 pages of transcripts, 939 medical articles, 50 expert reports, and hearing 
testimony from 28 experts, found that the MMR and thimerosal-containing vaccines, 
independently or together, were not causal factors in the development of autism or ASD [48, 
50, 140]. Finally, in Bruesewitz v. Wyeth (No. 09-152), the Supreme Court of the United States 
has held that the National Childhood Vaccine Injury Act “preempts all design-defect claims 
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against vaccine manufacturers brought by plaintiffs who seek compensation for injury or 
death caused by vaccine side effects” [141]. In so doing, it likely closed the door on 
thousands of claims by parents alleging a link between vaccines and childhood autism. 
13. Role of the media 
As described above, many parents are hesitant about vaccinating their children. Vaccine 
hesitancy can be explained in part by a lack of trust in those who make vaccine 
recommendations; a suspicion of profit motive driven by pharmaceutical companies; 
misinformation on the Internet; failure to appreciate the seriousness of vaccine-preventable 
diseases, given their low rates; and constant stories in the media claiming that vaccines 
cause a variety of illnesses, ranging from allergies to autism [135]. In spite of overwhelming 
scientific evidence to the contrary, the debate over vaccines and ASDs rages on, with media 
reports fueling the general public’s fear. The disconnect between the scientific community 
and the popular media is clear in a study published by researchers at the Stanford 
University School of Medicine [142]. They found that while 41 percent of research funding 
and published scientific papers on autism dealt with brain and behavior research, only 11 
percent of newspaper stories in the United States, United Kingdom and Canada dealt with 
those issues. Instead, 48 percent of the media coverage dealt with environmental causes of 
autism, particularly the childhood MMR vaccine [142]. However, in a study by Smith et al., 
there was a significant increase in selective MMR non-receipt in the US that was temporally 
associated with the publication of the original scientific literature suggesting a link between 
MMR and autism. This decline in MMR vaccination preceded media coverage of the MMR-
autism controversy and suggests a limited influence of mainstream media on MMR 
immunization in the United States [20].  
Poland and Jacobson note that there has been opposition to vaccination published in 
newspapers since the introduction of the first vaccine for smallpox over 200 years ago [143]. 
According to them, little has changed since that time, although now the antivaccinationists' 
media of choice are typically television and the Internet, including its social media outlets, 
which are used to sway public opinion and distract attention from scientific evidence [143]. 
The authors propose various remedies to the misinformation about vaccines that may be 
presented in the media. Chief among these is enhanced public education and public 
persuasion, with increasing scientific literacy at all levels of education. They also 
recommend public-private partnerships of scientists and physicians be developed to make 
accurate vaccine information accessible to the public in multiple languages, on a range of 
reading levels, and through various media outlets. 
14. Conclusions 
Due to the vaccine discoveries of the 20th century and implementation of successful 
immunization programs around the world, many infectious diseases such as smallpox, polio 
and measles have either been eradicated or become rare. Parents and many health care 
providers of the 21st century have limited or no experience with the devastating effects of 
these diseases. In parallel, over the last few decades there has been an alarming increase in 
the number of children diagnosed with autism spectrum disorders (ASDs). Why this 
increase has occurred is not entirely known, although some explanations have been offered 
by the medical and scientific community. ASDs are often diagnosed in children at about the 
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same chronologic age as the peak time for vaccine delivery. This congruence in time of two 
separate but important health issues, has led to the peculiar situation where fear of disease 
has shifted to concerns about vaccine safety, particularly ASDs among some members of the 
public. Although scientific evidence has refuted many of the misconceptions regarding 
vaccines and ASDs, this information has not been disseminated sufficiently among the lay 
public. The unfortunate result has been an erosion of public confidence in vaccines. 
Consequently, some vaccine-preventable diseases such as measles and polio have 
reappeared in parts of the world where they had been nearly eliminated. In order to restore 
the public’s trust, all stakeholders including parents, healthcare providers and public health 
authorities need to ensure that rigorously researched scientific information on the issue of 
vaccines and autism be accurately collected and disseminated. 
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